Evolus, Inc. (EOLS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -80%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.01, delivering a surprise of -83.33%.Over the last four quarters, the company has not been ...

Financial Data and Key Metrics Changes - Evolus reported global net revenue of $68.5 million for Q1 2025, representing a 15.5% increase compared to Q1 2024, supported by a strong commercial engine [6][15][12] - The company achieved a gross margin of 68.1% and an adjusted gross margin of 69.2% for the first quarter [18] - Non-GAAP operating loss for Q1 was $500,000, an improvement from a loss of $900,000 in Q1 2024, with expectations of achieving profitability in Q4 2025 [21][28] Business Line Data and Key Metrics Changes - Product revenue accounted for approximately 94% of total sales, with a customer reorder rate of about 70% [15] - The company added 675 new purchasing accounts, bringing the total to over 16,000, indicating strong market penetration [7] - The loyalty program saw over 220,000 redemptions, with 65% from existing consumers, highlighting high consumer satisfaction [8] Market Data and Key Metrics Changes - Evolus gained a 14% market share by the end of 2024, exceeding initial guidance, and continued to gain share in Q1 2025 [17] - International revenue contribution increased and is expected to outpace U.S. growth, validating the strong growth trajectory of the toxin business outside the U.S. [16] - The company reduced its toxin market growth expectation to low single digits for 2025, reflecting a more conservative outlook [6][17] Company Strategy and Development Direction - Evolus is transitioning into a multiproduct company with the launch of Evolisse, aiming to redefine the category and capture market share [8][11] - The company is focused on building long-term customer relationships and deepening its presence within existing accounts [11] - Evolus aims to achieve total net revenue of at least $700 million by 2028, with a compounded annual growth rate of 27% from 2024 [24][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging market environment while maintaining growth [14][12] - The early success of Evolisse is seen as a momentum builder, reinforcing growth across the portfolio [12] - Management reiterated full-year revenue guidance of $345 million to $355 million, projecting continued growth above 30% [27][28] Other Important Information - The company has taken proactive steps to strengthen its balance sheet through debt refinancing, reducing interest expenses and increasing cash generation [22][23] - Evolus is closely monitoring tariff impacts on its products, with limited exposure expected for 2025 [18][19] Q&A Session Summary Question: Market trends and demand changes - Management indicated that both macroeconomic factors and negative sentiment around the term "filler" are impacting demand, but they see an opportunity to revive the market segment [30][32] Question: Impact of AbbVie's loyalty program changes - Management acknowledged the impact of AbbVie's loyalty program changes on market dynamics but believes they continue to gain share despite this [44][46] Question: Confidence in 2025 revenue guidance - Management reiterated confidence in 2025 guidance due to accelerated share uptake despite slower market growth [54][56] Question: Early adopters of Evolisse - The initial adoption of Evolisse is primarily among existing customers, with high interest in trialing the product [65][66] Question: Seasonality and market softness - Management noted a consistent seasonal pattern but acknowledged slight slowing in new patient starts, impacting overall market dynamics [70][78]

Evolus (EOLS) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' First Quarter Earnings Conference Call. As a reminder, today's conference is being recorded and webcast live. All participants are in a listen only mode. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Narek Sargarian, Vice President and Head of Global Investor Relations and Corporate Commun ...

Revenue and Profitability - Product revenue increased by $9.2 million, or 15.5%, to $68.5 million for the three months ended March 31, 2025, compared to $59.3 million for the same period in 2024[175]. - Gross profit margin was 68.1% for the three months ended March 31, 2025, slightly down from 68.3% in the same period of 2024[177]. - Net loss for the three months ended March 31, 2025, was $18.9 million, compared to a net loss of $13.1 million for the same period in 2024[184]. Expenses - Selling, general and administrative expenses rose by $11.5 million, or 25.5%, to $56.6 million for the three months ended March 31, 2025, primarily due to increased personnel costs[177]. - Research and development expenses increased by $0.1 million, or 4.8%, to $2.2 million for the three months ended March 31, 2025, driven by clinical operations related to Evolysse[178]. - Cost of goods sold increased by $3.1 million, or 16.5%, to $21.9 million for the three months ended March 31, 2025, due to higher sales volume of Jeuveau[176]. Cash and Liquidity - Cash and cash equivalents as of March 31, 2025, were $67.9 million, with positive working capital of $75.5 million[183]. - Cash and cash equivalents at the end of the period were $67.9 million, down from $97.0 million at the end of March 31, 2024[199]. - For the three months ended March 31, 2025, operating activities used $15.6 million of cash, primarily due to a net loss of $18.9 million[200]. - Cash used in investing activities was $1.9 million for the three months ended March 31, 2025, compared to $0.8 million for the same period in 2024[202]. - Cash used in financing activities was $1.6 million for the three months ended March 31, 2025, compared to $45.7 million provided in the same period in 2024[203]. Future Obligations and Agreements - The company anticipates launching all four approved Evolysse products in Europe in the second half of 2025[172]. - The fair value of contingent royalty obligations payable to Evolus Founders was $2.2 million for the three months ended March 31, 2025, up from $1.6 million in the same period of 2024[179]. - As of March 31, 2025, the company recorded an aggregate balance of $44.6 million for future royalty payment obligations to Evolus Founders[189]. - The company has future interest payments on Pharmakon Term Loans totaling approximately $35.6 million, with $16.5 million due within twelve months[205]. - The company is obligated to make quarterly royalty payments to the Evolus Founders, which are a low single-digit percentage of net sales of Jeuveau[205]. - The company has milestone payments under the Symatese U.S. Agreement totaling €12.1 million, contingent on product approvals[205]. Distribution Rights - The company has exclusive distribution rights for Jeuveau in multiple regions, including the U.S., EU, and Japan, under the Daewoong Agreement[191]. - The company is required to meet minimum purchase obligations under the Daewoong Agreement to maintain exclusivity, contingent on market share and governmental approvals[191]. Debt and Financing - The Pharmakon Term Loans were amended to provide for a senior secured term loan of up to $250.0 million, with an initial tranche of $150.0 million funded upon agreement[187].

Evolus Reports First Quarter 2025 Results NEWPORT BEACH, Calif., May 7, 2025 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31, 2025. "Coming off a record year, we enter 2025 with strong momentum," said David Moatazedi, President and Chief Executive Officer of Evolus. "In our final quarter as a single-product company, we gained meaningful market share to st ...

Financial Data and Key Metrics Changes - In Q4 2024, global net revenue was $79 million, a 30% increase over Q4 2023 [31] - Full-year global net revenues reached $266.3 million, representing a 32% increase over 2023, exceeding the guidance range [31] - The company achieved profitability for the full year, one year ahead of expectations, with non-GAAP operating income of $6.7 million in Q4 2024 [36][29] Business Line Data and Key Metrics Changes - The US product revenues accounted for approximately 95% of total sales, with a customer reorder rate of about 70% [31] - The company added over 2,900 new accounts in 2024, bringing the total to more than 15,000 purchasing accounts [10] - Evolys Rewards surpassed 1.1 million users, growing 40% over the prior year [10] Market Data and Key Metrics Changes - The US market share approached 14% by the end of 2024, reflecting a consistent gain in market share [80] - The total addressable market for the company is approximately $6.2 billion today, expected to grow to around $10 billion by 2028 [40] - International revenue contribution is anticipated to increase, with the company targeting $100 million in international revenue by 2028 [11] Company Strategy and Development Direction - The launch of Evolys is a top priority, with plans to commercialize in early Q2 2025 [13] - The company aims to achieve at least $700 million in revenue by 2028, with a non-GAAP operating income margin of at least 20% [20] - The company is focusing on integrating Evolys into its existing portfolio, leveraging its cash pay model and consumer rewards [17] Management's Comments on Operating Environment and Future Outlook - Management noted a healthy market for toxins, with continued consumer interest and growth expected in the mid to high single digits [51] - The company is optimistic about the impact of the GLP-1 label on consumer interest and market dynamics [52] - Management expressed confidence in achieving profitability and positive non-GAAP operating income for the full year 2025 [42] Other Important Information - The company achieved a reported gross margin of 66.7% in Q4 2024, consistent with Q4 2023 [32] - Operating expenses grew at a rate less than half that of revenue, demonstrating continued operating leverage [34] - The company ended Q4 2024 with $87 million in cash, reflecting strong sales growth and efficient cash collection [37] Q&A Session Summary Question: How does the company view the market conditions for US facial injectables? - Management acknowledged challenging market conditions but noted strong growth in the toxin market and consumer interest, particularly among younger generations [47][48] Question: What are the early metrics for the Club Evolys subscription program? - Management reported good results from the initial rollout of the subscription program, with plans to evaluate its performance after a full year [56][58] Question: What are the growth expectations for the US toxin market in 2025? - Management projected a healthy growth rate for the toxin market, with expectations of mid to high single-digit growth [68] Question: How does the company differentiate its new fillers? - The company highlighted the unique Coldex technology used in Evolys, which offers better stability and performance compared to competitors [72][75] Question: What are the expectations for international revenue growth? - Management indicated that international revenue is expected to grow significantly faster than US revenue, contributing a larger share over time [93]

INVESTOR PRESENTATION MARCH 2025 2 DISCLOSURES FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product and pr ...

Financial Data and Key Metrics Changes - In 2024, the company achieved global net revenue of $266.3 million, a 32% increase over 2023, exceeding the guidance range of $260 million to $266 million [31] - The fourth quarter revenue was $79 million, reflecting a 30% increase compared to Q4 2023 [31] - The company reported a gross margin of 68.5% for the full year, with an adjusted gross margin of 69.6%, consistent with guidance [32] - Non-GAAP operating income for Q4 was $6.7 million, a significant improvement from a loss of $3.7 million in Q4 2023 [36] Business Line Data and Key Metrics Changes - The company added over 2,900 new accounts in 2024, bringing the total to more than 15,000 purchasing accounts, representing half of the toxin market [10] - The US market share approached 14% by the end of 2024, exceeding previous guidance [80] - The Evolys injectable gels are expected to contribute 8% to 10% of total revenue in 2025 [41] Market Data and Key Metrics Changes - The total addressable market for the company's products is approximately $6.2 billion, projected to grow to $10 billion by 2028 [40] - The company anticipates the US toxin market to grow in the mid to high single-digit range through 2028 [51] Company Strategy and Development Direction - The launch of Evolys is a top priority, with plans to commercialize in early Q2 2025 [13] - The company aims to achieve at least $700 million in revenue by 2028, with a non-GAAP operating income margin of at least 20% [20] - The company is focusing on integrating Evolys into its existing portfolio, leveraging a cash pay model and co-branded media benefits [17] Management's Comments on Operating Environment and Future Outlook - Management noted that despite challenging market conditions, the toxin market has shown consistent growth, particularly among younger consumers [48] - The company expressed confidence in its ability to capture market share and drive growth through innovative products and strategic partnerships [82] - Management highlighted the importance of the new weight loss label for Evolys, which is expected to attract new patients [52] Other Important Information - The company achieved profitability for the full year 2024, one year ahead of its goal [7] - The Evolys injectable gels utilize proprietary Coldex technology, which is expected to differentiate them from competitors [22] Q&A Session Summary Question: How does the company view the market conditions for US facial injectables? - Management acknowledged challenging market conditions but noted strong growth in the toxin market, particularly among younger consumers [48] Question: What are the expectations for the subscription model's performance? - The subscription model has shown good early results, but the company plans to wait for a full year cycle before sharing detailed metrics [56] Question: What are the growth expectations for the US toxin market in 2025? - Management projected a healthy growth rate for the toxin market, with expectations of mid to high single-digit growth [68] Question: How does the company plan to train accounts for the new Evolys products? - The company has developed a comprehensive training program and plans to train a significant number of accounts quickly [102] Question: What is the significance of the weight loss label for Evolys? - The weight loss label is expected to be a powerful marketing tool, attracting new patients seeking facial injectables [52]

Company Performance - Evolus, Inc. reported quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share, compared to a loss of $0.14 per share a year ago, representing an earnings surprise of -83.33% [1] - The company posted revenues of $78.95 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.08%, but showing an increase from year-ago revenues of $61 million [2] - Over the last four quarters, Evolus has not surpassed consensus EPS estimates, although it has topped consensus revenue estimates two times [2] Stock Performance - Evolus shares have increased by approximately 29.9% since the beginning of the year, while the S&P 500 has declined by -0.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $71.81 million, and for the current fiscal year, it is $0.21 on revenues of $351.93 million [7] Industry Outlook - The Medical - Products industry, to which Evolus belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________ FORM 10-K _____________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 _____________________________ EVOLUS, INC. (Exact name of registrant as speci ...